Comparison of Commercial Genetic-Testing Services in Korea with 23andMe Service
Table 1
The number of SNPs used for calculation of relative risk in three genetic services.
Category
The number of SNPs for all ethnic group (for Asian)
Number of overlapping SNPs among services
Hellogene Platinum
DNAGPS Optimus
23andMe
Lung cancer
1 (1)
3 (2)
1 (0)
0
Esophageal squamous cell cancer
2 (2)
5 (5)
1 (1)
2
(Hellogene and DNAGPS)
Colorectal caner
1 (1)
4 (3)
4 (2)
2
(DNAGPS and 23andMe)
Bladder cancer
1 (1)
3 (0)
6 (1) for male 7 (2) for female
1
(Three services)
Breast cancer (for female only)
1 (1)
5 (5)
8 (3)
1
(Hellogene and DNAGPS)
Atopic dermatitis
1 (1)
3 (1)
5 (1)
0
Rheumatoid arthritis
1 (1)
4 (4)
9 (2)
1
(DNAGPS and 23andMe)
Systemic lupus erythematosus
1 (1)
3 (3)
6 (4)
0
Psoriasis
2 (2)
4 (4)
3 (0)
1
(Hellogene and DNAGPS)
Diabetes mellitus, type 1
1 (1)
4 (0)
8 (0)
0
Body mass index (obesity)
1 (1)
2 (2)
10 (0)
1 2
(Three services) (DNAGPS and 23andMe)
Atrial fibrillation
1 (1)
2 (0)
2 (0)
1
(Hellogene and DNAGPS)
Coronary artery disease
1 (1)
7 (4)
15 (0)
0
0
Parkinson's disease
2 (2)
4 (4)
10 (4)
1 1
(Three services) (Hellogene and 23andMe)
Narcolepsy
1 (1)
2 (1)
1 (0)
0
Warfarin maintenance dose
1†
4‡
3‡
2
(DNAGPS and 23andMe)
Warfarin dosing of Hellogene Platinum was based on GGCX gene genotyping results. Warfarin dosing of DNAGPS Optimus and 23andMe was based on CYP2C9 and VKORC1 gene genotyping results.
